Globally, some 250 biotech companies are focusing on developing new drugs to combat AMR - The 40 BEAM members alone approx. 120 new drug candidates in their pipelines including many novel breakthrough ...
NEW YORK--(BUSINESS WIRE)-- Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of ...
New BEAM Alliance Position Paper calls out worldwide stakeholders to support SME-driven innovation and revive the product pipeline fighting antimicrobial resistance 2017 marks the beginning of a ...
Aptorum Group Limited, a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, announced it joined the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results